Synthesis, Biological Activity, and Molecular Modeling of Ribose-Modified Deoxyadenosine Bisphosphate Analogues as P2Y1 Receptor Ligands
- 26 July 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (5) , 829-842
- https://doi.org/10.1021/jm990249v
Abstract
The structure−activity relationships of adenosine-3‘,5‘-bisphosphates as P2Y1 receptor antagonists have been explored, revealing the potency-enhancing effects of the N6-methyl group and the ability to substitute the ribose moiety (Nandanan et al. J. Med. Chem. 1999, 42, 1625−1638). We have introduced constrained carbocyclic rings (to explore the role of sugar puckering), non-glycosyl bonds to the adenine moiety, and a phosphate group shift. The biological activity of each analogue at P2Y1 receptors was characterized by measuring its capacity to stimulate phospholipase C in turkey erythrocyte membranes (agonist effect) and to inhibit its stimulation elicited by 30 nM 2-methylthioadenosine-5‘-diphosphate (antagonist effect). Addition of the N6-methyl group in several cases converted pure agonists to antagonists. A carbocyclic N6-methyl-2‘-deoxyadenosine bisphosphate analogue was a pure P2Y1 receptor antagonist and equipotent to the ribose analogue (MRS 2179). In the series of ring-constrained methanocarba derivatives where a fused cyclopropane moiety constrained the pseudosugar ring of the nucleoside to either a Northern (N) or Southern (S) conformation, as defined in the pseudorotational cycle, the 6-NH2 (N)-analogue was a pure agonist of EC50 155 nM and 86-fold more potent than the corresponding (S)-isomer. The 2-chloro-N6-methyl-(N)-methanocarba analogue was an antagonist of IC50 51.6 nM. Thus, the ribose ring (N)-conformation appeared to be favored in recognition at P2Y1 receptors. A cyclobutyl analogue was an antagonist with IC50 of 805 nM, while morpholine ring-containing analogues were nearly inactive. Anhydrohexitol ring-modified bisphosphate derivatives displayed micromolar potency as agonists (6-NH2) or antagonists (N6-methyl). A molecular model of the energy-minimized structures of the potent antagonists suggested that the two phosphate groups may occupy common regions. The (N)- and (S)-methanocarba agonist analogues were docked into the putative binding site of the previously reported P2Y1 receptor model.Keywords
This publication has 44 references indexed in Scilit:
- Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptorsDrug Development Research, 2000
- Acyclic Analogues of Deoxyadenosine 3‘,5‘-Bisphosphates as P2Y1 Receptor AntagonistsJournal of Medicinal Chemistry, 2000
- Therapeutic applications of ATP-(P2)-receptors agonists and antagonistsExpert Opinion on Therapeutic Patents, 1999
- Conformational Analysis of Nucleosides Constructed on a Bicyclo[3.1.0]hexane Template. Structure-Antiviral Activity Analysis for the Northern and Southern Hemispheres of the Pseudorotational CycleNucleosides and Nucleotides, 1997
- (1S,2R)-[(Benzyloxy)methyl]cyclopent-3-enol. A Versatile Synthon for the Preparation of 4‘,1‘a-Methano- and 1‘,1‘a-Methanocarbocyclic NucleosidesThe Journal of Organic Chemistry, 1997
- Cloning and Tissue Distribution of the Human P2Y1ReceptorBiochemical and Biophysical Research Communications, 1996
- Cloning and functional expression of a brain G‐protein‐coupled ATP receptorFEBS Letters, 1993
- Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanicsJournal of Computational Chemistry, 1990
- A simple method for displaying the hydropathic character of a proteinJournal of Molecular Biology, 1982
- Conformational analysis of the sugar ring in nucleosides and nucleotides. New description using the concept of pseudorotationJournal of the American Chemical Society, 1972